Percheron Therapeutics Limited (ASX:PER)
Australia
· Delayed Price · Currency is AUD 0.0110
+0.0010 (10.00%)
May 30, 2025, 1:55 PM AEST
Percheron Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Operating Revenue | 2.97 | 2.97 | 1.96 | - | - | - | Upgrade
|
| Other Revenue | -1.05 | - | - | 1.78 | 0.58 | 0.67 | Upgrade
|
| Revenue | 1.92 | 2.97 | 1.96 | 1.78 | 0.58 | 0.67 | Upgrade
|
| Revenue Growth (YoY) | -28.14% | 51.07% | 10.51% | 207.72% | -13.56% | 13.91% | Upgrade
|
| Cost of Revenue | 0.12 | 0.06 | 0.03 | 0.07 | 0.11 | 0.2 | Upgrade
|
| Gross Profit | 1.8 | 2.91 | 1.93 | 1.71 | 0.47 | 0.46 | Upgrade
|
| Selling, General & Admin | 4.11 | 3.84 | 2.84 | 2.8 | 2.18 | 2.04 | Upgrade
|
| Research & Development | 12.74 | 10.7 | 10.16 | 4.54 | 4.91 | 1.9 | Upgrade
|
| Operating Expenses | 17.44 | 14.82 | 13.31 | 7.55 | 8.57 | 6.46 | Upgrade
|
| Operating Income | -15.63 | -11.91 | -11.38 | -5.83 | -8.11 | -6 | Upgrade
|
| Interest Expense | -0.01 | -0 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.03 | 0 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.07 | -0 | 0.01 | -0 | -0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -15.71 | -11.92 | -11.38 | -5.81 | -8.12 | -5.98 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.05 | 0.07 | Upgrade
|
| Pretax Income | -15.71 | -11.92 | -11.38 | -5.81 | -8.06 | -5.91 | Upgrade
|
| Net Income | -15.71 | -11.92 | -11.38 | -5.81 | -8.06 | -5.91 | Upgrade
|
| Net Income to Common | -15.71 | -11.92 | -11.38 | -5.81 | -8.06 | -5.91 | Upgrade
|
| Shares Outstanding (Basic) | 985 | 881 | 669 | 634 | 541 | 456 | Upgrade
|
| Shares Outstanding (Diluted) | 985 | 881 | 669 | 634 | 541 | 456 | Upgrade
|
| Shares Change (YoY) | 41.43% | 31.74% | 5.45% | 17.25% | 18.68% | 18.06% | Upgrade
|
| EPS (Basic) | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | -13.84 | -10.12 | -8.18 | -7.81 | -5.84 | -3.96 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 93.99% | 97.91% | 98.32% | 96.31% | 80.91% | 69.51% | Upgrade
|
| Operating Margin | -814.29% | -401.32% | -579.21% | -328.10% | -1402.91% | -897.30% | Upgrade
|
| Profit Margin | -818.38% | -401.57% | -579.19% | -326.89% | -1395.14% | -883.89% | Upgrade
|
| Free Cash Flow Margin | -721.02% | -340.93% | -416.36% | -439.23% | -1011.23% | -591.77% | Upgrade
|
| EBITDA | -15.63 | -11.9 | -11.37 | -5.83 | -8.1 | -5.99 | Upgrade
|
| D&A For EBITDA | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| EBIT | -15.63 | -11.91 | -11.38 | -5.83 | -8.11 | -6 | Upgrade
|
| Revenue as Reported | - | - | - | 1.81 | 0.64 | 0.77 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.